<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6531">
  <stage>Registered</stage>
  <submitdate>17/05/2017</submitdate>
  <approvaldate>17/05/2017</approvaldate>
  <nctid>NCT03165617</nctid>
  <trial_identification>
    <studytitle>Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects =2 to =18 Years of Age</studytitle>
    <scientifictitle>A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Influenza Comparator Vaccine in Subjects =2 to &lt;18 Years of Age</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002883-15</secondaryid>
    <secondaryid>V130_12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza, Human</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - QIVc
Other interventions - Non-influenza Comparator Vaccine

Experimental: QIVc (=2 years to &lt;18 Years of Age) - Cell-derived Seasonal Quadrivalent Influenza Vaccine

Active Comparator: Non-Influenza Comparator Vaccine - Non-Influenza Comparator Vaccine


Other interventions: QIVc
Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains

Other interventions: Non-influenza Comparator Vaccine
Non-influenza comparator vaccine for intramuscular use

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy: Absolute vaccine efficacy of QIVc by first occurrence Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) or culture confirmed influenza, due to any influenza Type A and B strain in subjects =3 years to &lt;18 years of age</outcome>
      <timepoint>Day 14 to Day 180 or until the end of the influenza season, whichever is longer</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Efficacy: Absolute vaccine efficacy of QIVc by first occurrence RT-PCR or culture confirmed influenza, due to any influenza Type A and B strain in subjects =2 years to &lt;18 years of age</outcome>
      <timepoint>Day 14 to Day 180 or until the end of the influenza season, whichever is longer</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: Absolute vaccine efficacy of QIVc by first occurrence RT-PCR or culture confirmed influenza, due to any influenza Type A and B strain by age subgroup</outcome>
      <timepoint>Day 14 to Day 180 or until the end of the influenza season, whichever is longer.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: Absolute vaccine efficacy of QIVc by first occurrence culture confirmed influenza, caused by influenza strains antigenically matched to the strains selected for the seasonal vaccine</outcome>
      <timepoint>Day 14 to Day 180 or until the end of the influenza season, whichever is longer.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: Absolute vaccine efficacy of QIVc determined by first occurrence RT-PCR influenza, due to any influenza Type A and B strain</outcome>
      <timepoint>Day 14 to Day 180 or until the end of the influenza season, whichever is longer.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: Absolute vaccine efficacy of QIVc determined by first occurrence culture confirmed influenza, due to any influenza Type A and B strain</outcome>
      <timepoint>Day 14 to Day 180 or until the end of the influenza season, whichever is longer.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity: Hemagglutination Inhibition (HI) Geometric mean titers (GMTs)</outcome>
      <timepoint>Day 1 (all subjects), Day 22 (all previously vaccinated subjects) or Day 29 and Day 50 (all not previously vaccinated subjects)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity: Percentage of subjects achieving seroconversion (seroconversion rate) for all 4 influenza strains</outcome>
      <timepoint>Day 22 (all previously vaccinated subjects) or Day 29 and Day 50 (all not previously vaccinated subjects)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity: HI Geometric Mean Ratio (GMR)</outcome>
      <timepoint>Day 22/Day 1 (all previously vaccinated subjects) or Day 29/Day 1 and Day 50/Day 1 (all not previously vaccinated subjects)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity: Percentage of subjects with HI titer = 1:40</outcome>
      <timepoint>Day 22 (all previously vaccinated subjects) or Day 29 and Day 50 (all not previously vaccinated subjects)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: The percentage of subjects with solicited local adverse events (AE)</outcome>
      <timepoint>Day 1 to Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: The percentage of subjects with solicited systemic AEs</outcome>
      <timepoint>Day 1 to Day 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: The percentage of subjects with all unsolicited AEs</outcome>
      <timepoint>Day 1 to Day 22 (for previously vaccinated subjects) or Day 1 to Day 50 (for not previously vaccinated subjects)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Percentage of subjects with SAEs, AEs leading to withdrawal from the study and New Onset of Chronic Diseases (NOCD)</outcome>
      <timepoint>Day 1 to Day 181 (for previously vaccinated subjects) or to Day 209 (for not previously vaccinated subjects)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Percentage of subjects with medically-attended AEs</outcome>
      <timepoint>Within 30 days of first occurrence of RT-PCR confirmed influenza-like-illness (ILI)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy males or females =2 years to &lt;18 years of age

          -  Individual who or whose parent(s) or legal guardian have given informed consent
             /assent after the nature of the study has been explained according to local regulatory
             requirements, prior to study entry

          -  Ability to comply with study procedures and are available for follow-up</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Hypersensitivity, including allergy to any component of vaccines foreseen in this
             study

          -  Abnormal function of the immune system

          -  Receipt of any influenza vaccine within 6 months prior to enrolment in this study or
             who plan to receive influenza vaccine while participating in the study.

          -  Pregnant or breastfeeding individual

          -  Female subject of childbearing potential, sexually active, and not used an acceptable
             method of birth control for at least 2 months prior to study entry and intend to use
             until the end of subject participation

        Additional eligibility criteria may be discussed by contacting the site.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>24/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>6368</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>17/03/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>AusTrials Pty Ltd - Sherwood</hospital>
    <hospital>Murdoch Childrens Research Institute - Carlton</hospital>
    <postcode>4075 - Sherwood</postcode>
    <postcode>3010 - Carlton</postcode>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Harjumaa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>JÃ¤rvamaa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kokkola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cavite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>National Capital Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Muang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Seqirus</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The randomized, observer-blind non-influenza comparator controlled study is intended to
      demonstrate the efficacy, immunogenicity, safety and tolerability of Seqirus' cell-based
      inactivated quadrivalent vaccine (QIVc) in subjects =2 years to &lt;18 years of age</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03165617</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Physician</name>
      <address>Seqirus</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Study Data Disclosure Manager</name>
      <address />
      <phone>Use Email</phone>
      <fax />
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>